A report of Epstein-Barr virus-positive primary cutaneous natural killer-/T-cell lymphoma

Sareeta R S Parker, Alvin Jr Solomon, Joshua E. Lane

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We describe a patient who presented with Epstein-Barr virus-positive tumor-stage primary cutaneous lymphoma. Our patient had previously been treated with oral methotrexate for long-standing rheumatoid arthritis. Tissue analysis revealed large tumor cells that were surface CD2- and CD3-positive; T-cell-restricted intracellular antigen-positive; CD56-, CD20-, and CD30-negative; and stained positively for Epstein-Barr virus. Our case is noteworthy for several reasons. Although the presence of rheumatoid arthritis and therapy with methotrexate are putative risk factors for the development of immune suppression-related and Epstein-Barr virus-related lymphomas, the vast majority of lymphomas in this setting are of B-cell origin, and rarely are these primary cutaneous in nature. In addition, our patient's tumor displayed an unusual phenotype, with immunophenotypic features suggestive of an atypical natural killer-/T-cell lymphoma. Methotrexate was withdrawn, and our patient was successfully treated with local radiotherapy. She has remained in complete remission 28 months since diagnosis.

Original languageEnglish (US)
Pages (from-to)157-161
Number of pages5
JournalJournal of the American Academy of Dermatology
Volume59
Issue number1
DOIs
StatePublished - Jul 2008
Externally publishedYes

Fingerprint

Natural Killer T-Cells
T-Cell Lymphoma
Human Herpesvirus 4
Methotrexate
Lymphoma
Skin
Rheumatoid Arthritis
Neoplasms
B-Lymphocytes
Radiotherapy
T-Lymphocytes
Phenotype
Antigens
Therapeutics

ASJC Scopus subject areas

  • Dermatology

Cite this

A report of Epstein-Barr virus-positive primary cutaneous natural killer-/T-cell lymphoma. / Parker, Sareeta R S; Solomon, Alvin Jr; Lane, Joshua E.

In: Journal of the American Academy of Dermatology, Vol. 59, No. 1, 07.2008, p. 157-161.

Research output: Contribution to journalArticle

Parker, Sareeta R S ; Solomon, Alvin Jr ; Lane, Joshua E. / A report of Epstein-Barr virus-positive primary cutaneous natural killer-/T-cell lymphoma. In: Journal of the American Academy of Dermatology. 2008 ; Vol. 59, No. 1. pp. 157-161.
@article{9f565f79e65947de8a4c98fad5df783c,
title = "A report of Epstein-Barr virus-positive primary cutaneous natural killer-/T-cell lymphoma",
abstract = "We describe a patient who presented with Epstein-Barr virus-positive tumor-stage primary cutaneous lymphoma. Our patient had previously been treated with oral methotrexate for long-standing rheumatoid arthritis. Tissue analysis revealed large tumor cells that were surface CD2- and CD3-positive; T-cell-restricted intracellular antigen-positive; CD56-, CD20-, and CD30-negative; and stained positively for Epstein-Barr virus. Our case is noteworthy for several reasons. Although the presence of rheumatoid arthritis and therapy with methotrexate are putative risk factors for the development of immune suppression-related and Epstein-Barr virus-related lymphomas, the vast majority of lymphomas in this setting are of B-cell origin, and rarely are these primary cutaneous in nature. In addition, our patient's tumor displayed an unusual phenotype, with immunophenotypic features suggestive of an atypical natural killer-/T-cell lymphoma. Methotrexate was withdrawn, and our patient was successfully treated with local radiotherapy. She has remained in complete remission 28 months since diagnosis.",
author = "Parker, {Sareeta R S} and Solomon, {Alvin Jr} and Lane, {Joshua E.}",
year = "2008",
month = "7",
doi = "10.1016/j.jaad.2008.03.036",
language = "English (US)",
volume = "59",
pages = "157--161",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - A report of Epstein-Barr virus-positive primary cutaneous natural killer-/T-cell lymphoma

AU - Parker, Sareeta R S

AU - Solomon, Alvin Jr

AU - Lane, Joshua E.

PY - 2008/7

Y1 - 2008/7

N2 - We describe a patient who presented with Epstein-Barr virus-positive tumor-stage primary cutaneous lymphoma. Our patient had previously been treated with oral methotrexate for long-standing rheumatoid arthritis. Tissue analysis revealed large tumor cells that were surface CD2- and CD3-positive; T-cell-restricted intracellular antigen-positive; CD56-, CD20-, and CD30-negative; and stained positively for Epstein-Barr virus. Our case is noteworthy for several reasons. Although the presence of rheumatoid arthritis and therapy with methotrexate are putative risk factors for the development of immune suppression-related and Epstein-Barr virus-related lymphomas, the vast majority of lymphomas in this setting are of B-cell origin, and rarely are these primary cutaneous in nature. In addition, our patient's tumor displayed an unusual phenotype, with immunophenotypic features suggestive of an atypical natural killer-/T-cell lymphoma. Methotrexate was withdrawn, and our patient was successfully treated with local radiotherapy. She has remained in complete remission 28 months since diagnosis.

AB - We describe a patient who presented with Epstein-Barr virus-positive tumor-stage primary cutaneous lymphoma. Our patient had previously been treated with oral methotrexate for long-standing rheumatoid arthritis. Tissue analysis revealed large tumor cells that were surface CD2- and CD3-positive; T-cell-restricted intracellular antigen-positive; CD56-, CD20-, and CD30-negative; and stained positively for Epstein-Barr virus. Our case is noteworthy for several reasons. Although the presence of rheumatoid arthritis and therapy with methotrexate are putative risk factors for the development of immune suppression-related and Epstein-Barr virus-related lymphomas, the vast majority of lymphomas in this setting are of B-cell origin, and rarely are these primary cutaneous in nature. In addition, our patient's tumor displayed an unusual phenotype, with immunophenotypic features suggestive of an atypical natural killer-/T-cell lymphoma. Methotrexate was withdrawn, and our patient was successfully treated with local radiotherapy. She has remained in complete remission 28 months since diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=45049088590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45049088590&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2008.03.036

DO - 10.1016/j.jaad.2008.03.036

M3 - Article

VL - 59

SP - 157

EP - 161

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 1

ER -